• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缓释烟酸与辛伐他汀固定剂量复方制剂用于治疗脂质紊乱

Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.

作者信息

Vo Anthony N, Kashyap Moti L

机构信息

Atherosclerosis Research Center, Department of Veteran Affairs Healthcare System, 5901 E. Seventh Street, Long Beach, CA 90822, USA.

出版信息

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1303-10. doi: 10.1586/14779072.6.10.1303.

DOI:10.1586/14779072.6.10.1303
PMID:19018682
Abstract

Coronary heart disease (CHD) carries significant morbidity and mortality worldwide. Elevated LDL-cholesterol and reduced HDL-cholesterol levels are well-recognized CHD risk factors. Despite guideline recommendations for intensive therapy among patients at high risk for CHD to lower LDL-cholesterol, such lowering has failed to prevent approximately two-thirds of cardiovascular events. As a result of new data, guidelines have begun to focus on non-HDL-cholesterol, HDL-cholesterol and triglycerides as treatment targets, with the end result being a recommendation for combination therapy, such as niacin plus statin for the treatment of dyslipidemia. Compared with statin monotherapy, a combination of niacin and statin therapy provides beneficial effects on a broad range of lipid particles and some evidence suggests a further reduction in CHD risk. Recent studies have shown that the combination of a fixed dose of extended-release niacin plus simvastatin reduces non-HDL-cholesterol, LDL-cholesterol, triglycerides and total cholesterol:HDL-cholesterol ratio by approximately 50% while increasing HDL-cholesterol by 25%. The safety of this combination is consistent with the safety profiles of each individual component and is well tolerated. A long-term study is currently being conducted to evaluate whether this combination therapy confers an additive impact on clinical end points.

摘要

冠心病(CHD)在全球范围内都具有显著的发病率和死亡率。低密度脂蛋白胆固醇(LDL - C)升高和高密度脂蛋白胆固醇(HDL - C)水平降低是公认的冠心病危险因素。尽管有指南建议对冠心病高危患者进行强化治疗以降低LDL - C,但这种降低未能预防约三分之二的心血管事件。由于新的数据,指南已开始将非HDL - C、HDL - C和甘油三酯作为治疗靶点,最终结果是推荐联合治疗,如使用烟酸加他汀类药物治疗血脂异常。与他汀类药物单药治疗相比,烟酸与他汀类药物联合治疗对多种脂质颗粒具有有益作用,并且一些证据表明可进一步降低冠心病风险。最近的研究表明,固定剂量的缓释烟酸加辛伐他汀联合用药可使非HDL - C、LDL - C、甘油三酯和总胆固醇:HDL - C比值降低约50%,同时使HDL - C升高25%。这种联合用药的安全性与各单一成分的安全性相符,且耐受性良好。目前正在进行一项长期研究,以评估这种联合治疗是否对临床终点有附加影响。

相似文献

1
Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.缓释烟酸与辛伐他汀固定剂量复方制剂用于治疗脂质紊乱
Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1303-10. doi: 10.1586/14779072.6.10.1303.
2
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.长期安全性和疗效的三联组合依折麦布/辛伐他汀加烟酸缓释在高脂血症患者。
Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13.
3
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.依折麦布/辛伐他汀与缓释烟酸联合给药对IIa型或IIb型高脂血症患者的血脂调节疗效及安全性
J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003.
4
A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.联合治疗血脂异常的新模式:拉罗匹仑+烟酸+辛伐他汀。
Expert Opin Investig Drugs. 2010 Mar;19(3):437-49. doi: 10.1517/13543781003623223.
5
An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.一项关于不溶性药物递送微粒非诺贝特与阿托伐他汀、辛伐他汀及缓释烟酸联合使用在健康志愿者体内药代动力学的开放标签、交叉研究。
Clin Ther. 2006 Jan;28(1):45-54. doi: 10.1016/j.clinthera.2005.12.004.
6
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).烟酸缓释片与辛伐他汀联合片剂和辛伐他汀单药治疗对非高密度脂蛋白胆固醇升高患者的安全性和疗效比较(来自SEACOAST I研究)
Am J Cardiol. 2008 May 15;101(10):1428-36. doi: 10.1016/j.amjcard.2008.02.092.
7
Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.基于模型的模拟,以探讨遵循糖尿病和混合性血脂异常患者甘油三酯和低密度脂蛋白胆固醇控制实践指南的成本效益。
Clin Ther. 2009 Apr;31(4):862-79. doi: 10.1016/j.clinthera.2009.04.015.
8
Niacin-based therapy for dyslipidemia: past evidence and future advances.基于烟酸的血脂异常治疗:过去的证据与未来的进展
Am J Manag Care. 2002 Sep;8(12 Suppl):S315-22.
9
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.缓释烟酸/拉罗匹仑对原发性高胆固醇血症或混合性血脂异常患者的脂质调节疗效及耐受性
Int J Clin Pract. 2008 Dec;62(12):1959-70. doi: 10.1111/j.1742-1241.2008.01938.x.
10
Safety of niacin and simvastatin combination therapy.烟酸与辛伐他汀联合治疗的安全性。
Am J Cardiol. 2008 Apr 17;101(8A):3B-8B. doi: 10.1016/j.amjcard.2008.02.026.

引用本文的文献

1
Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcome.尼可占替诺和辛伐他汀联合治疗实验性中风,可减少轴突损伤,改善功能预后。
J Neurol Sci. 2010 Jul 15;294(1-2):107-11. doi: 10.1016/j.jns.2010.03.020. Epub 2010 May 7.